Trial Profile

An Open-label, Multi-center Phase II Trial to evaluate the efficacy and Safety of Combination Chemotherapy With DoceTaxel and Gemcitabine

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Gemcitabine (Primary)
Indications Advanced breast cancer
Focus Therapeutic Use
Acronyms NeoTG

Most Recent Events

19 Jan 2012 Additional lead trial centre (Yuhan corporation) identified as reported by Clinical Research Information Service (CriS) - Republic of Korea.
19 Jan 2012 Actual initiation date (8 Dec 2011) added as reported by Clinical Research Information Service (CriS) - Republic of Korea.
19 Jan 2012 Status changed from not yet recruiting to recruiting as reported by Clinical Research Information Service (CriS) - Republic of Korea.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com